Woodside Capital says life sciences venture funding rises to $15 billion in Q1 2026

  • Woodside Capital Partners’ Q1 2026 life sciences update flagged a rebound in median TTM revenue growth to 3.9% from 0.1% a year earlier.
  • Median revenue rose to USD 636 million, pointing to improved operating momentum across the tracked cohort.
  • Global life sciences, healthcare M&A hit 299 deals in March 2026, with monthly deal value of USD 66 billion.
  • Life sciences venture funding totaled USD 15 billion in Q1 2026, broadly in line with the improving 2025 funding backdrop.
  • The WCP Life Sciences Index gained 6% since September 2025, beating the S&P 500’s 2.4% decline over the same span.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Woodside Capital Partners published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.